Cow's Milk Allergy Clinical Trial
Official title:
Cow's Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula (TeHF2013-01) in Infants With Confirmed Cow's Milk Protein Allergy
Cow's milk protein allergy is defined as an immunological reaction to one or more milk
proteins. A variety of symptoms can be suggestive for cow's milk protein allergy . Cow's
milk protein allergy is suspected clinically in 5-15% of infants, while most estimates of
prevalence of cow's milk protein allergy vary from only 2 to 5 %. Confusion regarding cow's
milk protein allergy prevalence is often due to differences in study populations, study
design and a lack of defined diagnostic criteria. The importance of defined diagnostic
criteria needs to be emphasised. It precludes infants from an unnecessary diet and avoids
delay in diagnosis, which can lead to malnutrition.
There are two clinical types of cow's milk protein allergy: the immediate and the delayed
type. The immediate type usually presents within minutes after the ingestion of cow's milk
protein with urticaria, angio-oedema, vomiting or an acute flare of atopic dermatitis and is
present in slightly more than half of the patients with cow's milk protein allergy. Delayed
reactions such as atopic dermatitis or gastrointestinal symptoms like proctocolitis or
enteropathy usually present after hours or days.
Immunologically, cow's milk protein allergy can be IgE or non-IgE mediated. IgE mediated
reactions are often of the immediate type. Non-IgE mediated reactions are often cell
mediated or mixed cell and IgE mediated and are more difficult to prove by specific testing.
The immunological reaction differentiates cow's milk protein allergy from other milk induced
pathology such as lactose intolerance.
A variety of symptoms can be suggestive for cow's milk protein allergy although none of them
is diagnostic. A good medical history remains the cornerstone for the diagnosis.
The treatment of cow's milk protein allergy is the dietary elimination of cow's milk
proteins. In non-breastfed infants and children less than 2 years of age, a substitute
formula is mandatory as prescribed by several international scientific societies.
Extensively hydrolyzed formulas are used as therapeutic formulas. An extensively hydrolysed
formula is often a whey or casein based formula in which the protein has been chopped up in
smaller pieces that are less allergenic. Because of high cross-reactivity (up to 80%) and
nutritional inadequacy, the use of any other animal milk or soy-based formula is
precluded.The infant should be maintained on an elimination diet until the child is between
9-12 months of age or at least for 6 months, whichever occurs first. In most cases, symptoms
will improve substantially within 2-4 weeks if diagnosis is correct.
According to consensus in literature, a therapeutic formula is a formula tolerated by at
least 90% (with 95% confidence) of cow's milk protein allergy infants.
The aim of the investigators study is to show the efficacy, tolerance and nutritional
adequacy of a newly developed thickened extensively hydrolyzed formula in infants with a
proven cow's milk protein allergy. In all included patients, cow's milk protein allergy will
have been diagnosed based on a double blind placebo controlled food challenge, considered as
golden standard in cow's milk protein allergy diagnosis. To evaluate efficacy of the
formula, the formula has to be tolerated by at least 90% (with 95% confidence) of cow's milk
protein allergy infants following literature consensus. A symptom diary will be filled out
for this purpose by the patients' parents or legal guardians and the patient will be
followed clinically by his doctor several times during the study period.
Nutritional adequacy of the formula will be evaluated clinically by following growth and
weight several times during the study period and by comparing it to the standard WHO growth
curves, based on breastfed infants.
Status | Recruiting |
Enrollment | 29 |
Est. completion date | July 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Month to 12 Months |
Eligibility |
Inclusion Criteria: - between 1 and 12 months old - having a CMPA confirmed by a double-blind placebo controlled food challenge performed in the last 3 months, or with cow's milk allergy highly suspected based on clinical symptoms ( but not confirmed. In this case, a double blind food challenge will be performed during the first 3 months following inclusion - whose parent(s) signed the informed consent form Exclusion Criteria: - Infants aged less than 1 month or more than 12 months - Infants with eosinophilic disorders of the gastrointestinal tract - Infants mainly or exclusively breastfed, with willingness to continue breast-feeding - Infants having a weight at inclusion < 2500g, - Infants fed (at the time of inclusion or in the past) with an extensively hydrolyzed formula with no improvement of the symptoms, - Infants who refused to drink an extensively hydrolyzed formula anytime prior to inclusion, - Infants fed with a vegetable based formula , - Infants fed an amino acid based formula - Infants who should be fed with an amino acid based formula according to recommendations - Infants who had an anaphylactic reaction in the past, - Infants presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject, such as, but not limited to , concomitant chronic systemic diseases, congenital cardiac defects, active tuberculosis, autoimmune diseases, immunodeficiency, chronic inflammatory bowel diseases, celiac disease, cystic fibrosis, metabolic diseases, lactose intolerance, malignancy, chronic pulmonary diseases, malformations of the gastrointestinal tract. - Infants already participating in another clinical trial. |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | University of Naples Federico II | Naples |
Lead Sponsor | Collaborator |
---|---|
Federico II University |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of subjects tolerants to a new hypoallergenic formula demonstrated by oral food challenge with the new study formula. | All subjects perform an oral food challenge with the new study formula. If the infant not react to the new hypoallergenic formula during the oral food challenge, the subjects tolerate this product and will assume it every day for 4 months, as treatment for cow's milk allergy. | At the moment of oral food challenge | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02738060 -
The Effect of Baked Milk on Cow's Milk Allergy
|
Phase 2 | |
Recruiting |
NCT01891916 -
Effect Of Lactobacillus GG on Atopic March
|
N/A | |
Completed |
NCT01634490 -
Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy
|
N/A | |
Completed |
NCT01622426 -
Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy
|
N/A | |
Completed |
NCT02466035 -
Epigenetic Effects Involved in Children With Cow's Milk Allergy (EPICMA)
|
N/A | |
Completed |
NCT02379598 -
Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy
|
N/A | |
Completed |
NCT04330092 -
Diagnosis of Cow's Milk Protein Allergy
|
||
Not yet recruiting |
NCT02081651 -
Parmigiano-Reggiano Cheese as a Possible Strategy to Acquire Oral Tolerance in Children With Cow's Milk Allergy
|
Phase 3 | |
Completed |
NCT03462030 -
Baked Milk Oral Immunotherapy for Cow's Milk Allergy
|
Phase 2 | |
Completed |
NCT02465905 -
Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : "Petit Lait" Study
|
N/A | |
Suspended |
NCT05731206 -
Hypoallergenicity of a Hydrolyzed Protein Infant Formula
|
N/A | |
Not yet recruiting |
NCT06456541 -
Infant Formula in Infants and Children With Cow's Milk Allergy
|
N/A | |
Recruiting |
NCT02062476 -
Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's Milk Allergy
|
Phase 2 | |
Completed |
NCT01589731 -
Polymerized Beta-lactoglobulin Comparative Immunoreactivity
|
N/A | |
Terminated |
NCT02405923 -
Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy
|
N/A | |
Terminated |
NCT04910373 -
Extensively Hydrolyzed Infant Formula in Infants and Children With Cow's Milk Allergy
|
N/A | |
Recruiting |
NCT01968278 -
Use of Baked Milk in Oral Immunotherapy for Severe IgE-mediated Cow's Milk Protein Allergic Patients
|
N/A | |
Withdrawn |
NCT01470768 -
Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based (AA) Formulas
|
N/A | |
Recruiting |
NCT05883384 -
Validity of Cow's Milk-related Symptom Score Among Children Suspected to Have Cow's Milk Protein Alergy
|
||
Completed |
NCT01901380 -
Cow's Milk Allergy and Functional Gastrointestinal Disorders
|
N/A |